CTNNB1 and neoplasm: To extrapolate our findings to additional β-catenin-mutated HCC preclinical models that we have previously reported, we next tested LNP-CTNNB1 in the more aggressive S45Y-mutant-β-catenin-Met (β-M) model, which represents 11% of human HCC.26 Here, we started treatment at 3-weeks post-HDTVi, a timepoint when microscopic tumor foci are established.